The challenge now is to turn our strengths into globally competitive companies that retain more intellectual property, jobs, and economic value in Canada.
From insulin to regenerative therapy, Canada’s contribution to diabetes research is unmatched. The question is whether we’ll continue to lead or watch others cross the finish line.